Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Toll-Free Screening, Advice Service Would Enchance OTC Mevacor - Merck

This article was originally published in The Tan Sheet

Executive Summary

Merck would support an OTC version of its statin drug Mevacor with an ambitious customer education program that would ensure proper usage of the cholesterol-lowering medication, the firm stated July 13 at a joint meeting of FDA's Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees.

You may also be interested in...



Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins

A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show

Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins

A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show

Mevacor OTC Study Shows Cholesterol-Lowering Consistent With Rx Statins

A cholesterol self-management program for OTC Mevacor was effective in deterring consumers from improperly purchasing the nonprescription version of the cholesterol-lowering drug, results from the CUSTOM actual-use study show

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel